Please use this identifier to cite or link to this item:
Title: Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
Authors: Zozaya González, Mª Neboa 
Abdalla, Fernando
Alfonso Zamora, Santiago
Balea Filgueiras, Jesús
Carrascosa Carrillo, José Manuel
Delgado Sánchez, Olga
Dolz Sinisterra, Francisco
García-Ruiz, Antonio
Herranz Pinto, Pedro
Manfredi, Antonio
Martínez Olmos, José
Morales de Los Ríos Luna, Paloma
Puig, Lluis
Ros, Sandra
HIdalgo-Vega, Álvaro
UNESCO Clasification: 32 Ciencias médicas
320106 Dermatología
3209 Farmacología
Keywords: Bimekizumab
Multi-Criteria Decision Analysis, et al
Issue Date: 2022
Journal: Expert Review of Pharmacoeconomics and Outcomes Research 
Abstract: Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. Research design and methods: The EVIDEM framework was adapted to reflect relevant criteria for the assessment. Estimated values were obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 12 experts. Consistency and replicability were evaluated through an alternative weighting method and a re-test. Results: Bimekizumab was assessed by the committee as an intervention with a positive value contribution for the treatment of moderate-to-severe psoriasis in comparison to any of the alternatives. The drug provides a substantial therapeutical benefits and improves the health results reported by the patients, as it combines a higher level of clearance, rapidity, and persistence with a similar safety and tolerability profile. Conclusions: Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives.
ISSN: 1473-7167
DOI: 10.1080/14737167.2022.2063842
Source: Expert Review of Pharmacoeconomics and Outcomes Research [ISSN 1473-7167], (Abril 2022)
Appears in Collections:Artículos
Adobe PDF (2,81 MB)
Show full item record


checked on May 19, 2024

Page view(s)

checked on Apr 28, 2024


checked on Apr 28, 2024

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.